Key facts
- It has raised $9.5M; the latest was Later Stage VC ($3.0M) in Aug 2024.
- Notable investors include OurCrowd, The Leona M. and Harry B. Helmsley Charitable Trust, Roman Abramovich, A-Labs, Mark Suss — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for DreaMed
- ·The full record, as it builds
Funding rounds
No funding rounds for DreaMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DreaMed
Developer of a diabetes management system designed to optimize intensive insulin therapy. The company's system uses event-driven machine learning and logic technology to process multiple personalized parameters such as insulin delivery data, glucose readings, meal data, and optimized insulin dosing treatment plans, enabling care providers and patients to improve living standards and lower overall treatment costs.
- Sector
- Healthcare
- HQ
- Petah Tikva, Israel
- Founded
- 2014
- Employees
- 20
- Website
- dreamed.ai/
- Ownership
- Privately Held (backing)
DreaMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DreaMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DreaMed in its N-PORT filings yet. We sweep new filings monthly.